ARCHIMED to Take ZimVie Private in $730 Million Deal

ARCHIMED to Acquire Esperion Therapeutics in Up to $1.1B Deal

May 1, 2026

Healthcare Services

ARCHIMED, via a fund-managed affiliate, signed a definitive agreement to acquire Esperion Therapeutics for $3.16 per share in cash, valuing the transaction at up to approximately $1.1 billion including commercial milestone payments. Esperion shareholders will also receive a contingent value right (CVR) for up to $100 million in additional milestones tied to future U.S. net sales of bempedoic acid- and bumetanide-containing products.

ARCHIMED Acquires BioVendor Group

March 11, 2025

Medical Devices

ARCHIMED, a Europe-focused private equity firm specializing in healthcare, has acquired BioVendor Group, a Brno-headquartered developer and manufacturer of in‑vitro diagnostics and immunoassays. ARCHIMED will partner with existing management to accelerate internationalization, product innovation and commercial expansion as part of its MED III fund's diagnostics investment strategy.

ARCHIMED (MED Platform II) Acquires Jeisys Medical

September 11, 2024

Medical Devices

ARCHIMED, via its MED Platform II fund, has agreed a ₩990 billion take-private acquisition of Jeisys Medical, a Seoul-based developer of energy-based aesthetic medicine devices. The transaction will delist Jeisys from the Korea Exchange and support the company’s international expansion, with founder Dong Hwan Kang reinvesting a material portion of his proceeds into the privatized business.

ARCHIMED Acquires Majority Stake in Cardioline

November 17, 2021

Medical Devices

Trans-Atlantic private equity firm ARCHIMED has acquired a majority stake in Cardioline, a Trento, Italy-based maker of cardiology devices and Europe's largest provider of cardiology-focused telemedicine. The investment, made through ARCHIMED's MED III Fund, will support Cardioline's product and software development, international expansion and potential add-on M&A while founders retain a significant minority stake and remain in management.

ARCHIMED Acquires Majority Stake in Germany's Zyto Group

January 12, 2021

Medical Devices

ARCHIMED, through its MED II fund, has acquired a majority stake in the Zyto group — a German developer, manufacturer and distributor of advanced cancer diagnostics, including Zytomed, ZytoVision and 42 Life Sciences. The deal will keep founders and management as significant minority shareholders and is intended to accelerate product innovation, regulatory capabilities and international expansion of the group's precision oncology diagnostics.

ARCHIMED Acquires 75% Stake in ActiGraph

May 18, 2020

Medical Devices

ARCHIMED (ArchiMed) has acquired a 75% stake in ActiGraph in an all-equity transaction, with management retaining 10% and other historic shareholders keeping 15%. The investment will fund ActiGraph's expansion into the regulated drug-development and clinical-trials market, accelerating product, regulatory and commercial capabilities; financial terms were not disclosed.